| 1 |
Liu S, Zhang Z, Yan S, et al. Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives [J]. Front Oncol, 2025, 15: 1503140.
|
| 2 |
Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment [J]. Am J Clin Dermatol, 2020, 21(3): 339-353.
|
| 3 |
Motomura K, Yamashita H, Yamada S, et al. Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study [J]. Rheumatol Int, 2019, 39(10): 1733-1739.
|
| 4 |
Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study [J]. J Rheumatol, 2015, 42(2): 282-291.
|
| 5 |
Leatham H, Schadt C, Chisolm S, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts [J]. Medicine (Baltimore), 2018, 97(2): e9639.
|
| 6 |
Lauinger J, Ghoreschi K, Volc S. Characteristics of dermatomyositis patients with and without associated malignancy [J]. J Dtsch Dermatol Ges, 2021, 19(11): 1601-1611.
|
| 7 |
Chang L, Zhang L, Jia H, et al. Malignancy in dermatomyositis: a retrospective paired case-control study of 202 patients from Central China [J]. Medicine (Baltimore), 2020, 99(34): e21733.
|
| 8 |
Ungprasert P, Leeaphorn N, Hosiriluck N, et al. Clinical features of inflammatory myopathies and their association with malignancy: a systematic review in asian population [J]. ISRN Rheumatol, 2013, 2013: 509354.
|
| 9 |
Adamska U, Białecka A, Mêcińska-Jundziłł K, et al. Dermatomyositis associated with gastrointestinal malignancies - report of two cases and a literature review [J]. Postepy Dermatol Alergol, 2021, 38(2): 343-345.
|
| 10 |
Adhikari K, Pant P, Bhandari S, et al. Dermatomyositis with positive anti-TIF1 gamma antibodies in an adult female: a case report [J]. Clin Case Rep, 2023, 11(11): e8215.
|
| 11 |
Wang Y, Yuan Q, Zhao Y, et al. The immune response to the dermatomyositis-specific autoantigen nuclear matrix protein 2 can result in experimental autoimmune myositis [J]. Ann Rheum Dis, 2025, 84(8): 1442-1444.
|
| 12 |
Che WI, Baecklund F, Hellgren K, et al. Familial co-aggregation of idiopathic inflammatory myopathies and cancer: a Swedish population-based study [J]. Arthritis Rheumatol, 2023, 75(8): 1445-1455.
|
| 13 |
Mammen AL, Allenbach Y, Stenzel W, et al. 239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 december 2018 [J]. Neuromuscul Disord, 2020, 30(1): 70-92.
|
| 14 |
Parks CG, Wilkerson J, Rose KM, et al. Association of ultraviolet radiation exposure with dermatomyositis in a national myositis patient registry [J]. Arthritis Care Res (Hoboken), 2020, 72(11): 1636-1644.
|
| 15 |
Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, et al. Classification and management of adult inflammatory myopathies [J]. Lancet Neurol, 2018, 17(9): 816-828.
|
| 16 |
Zhou H, Wang Y, Bi K, et al. Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients [J]. Clin Rheumatol, 2019, 38(5): 1425-1431.
|
| 17 |
Marzęcka M, Niemczyk A, Rudnicka L. Autoantibody markers of increased risk of malignancy in patients with dermatomyositis [J]. Clin Rev Allergy Immunol, 2022, 63(2): 289-296.
|
| 18 |
Patasova K, Lundberg IE, Holmqvist M. Genetic influences in cancer-associated myositis [J]. Arthritis Rheumatol, 2023, 75(2): 153-163.
|
| 19 |
Mann H, Kryštůfková O, Zámečník J, et al. Interleukin-35 in idiopathic inflammatory myopathies [J]. Cytokine, 2021, 137: 155350.
|
| 20 |
Selva-O'Callaghan A, Ros J, Gil-Vila A, et al. Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes [J]. Neuromuscul Disord, 2019, 29(11): 819-825.
|
| 21 |
Wang Y, Cao X, Yang C, et al. Ferroptosis and immunosenescence in colorectal cancer [J]. Semin Cancer Biol, 2024, 106-107: 156-165.
|
| 22 |
Jayan A, Mammen AL, Suarez-Almazor ME. Immune checkpoint inhibitor-induced myositis [J]. Rheum Dis Clin North Am, 2024, 50(2): 281-290.
|
| 23 |
Moreira A, Loquai C, Pföhler C, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors [J]. Eur J Cancer, 2019, 106: 12-23.
|
| 24 |
Allenbach Y, Anquetil C, Manouchehri A, et al. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities [J]. Autoimmun Rev, 2020, 19(8): 102586.
|
| 25 |
孙茹蓉, 喻少波, 王静, 等. 多发性肌炎和皮肌炎临床特点回顾性分析308例 [J/OL]. 中华临床医师杂志(电子版), 2018, 12(6): 321-326.
|
| 26 |
Fardet L, Dupuy A, Gain M, et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis [J]. Medicine (Baltimore), 2009, 88(2): 91-97.
|
| 27 |
Wang YF, Li HX, Feng Y, et al. [Risk factors analysis and prediction model establishment of malignant tumor in patients with polymyositis/dermatomyositis] [J]. Zhonghua Yi Xue Za Zhi, 2023, 103(25): 1903-1910. Chinese.
|
| 28 |
Ponyi A, Constantin T, Garami M, et al. Cancer-associated myositis: clinical features and prognostic signs [J]. Ann N Y Acad Sci, 2005, 1051: 64-71.
|
| 29 |
Lu X, Peng Q, Wang G. The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome [J]. Curr Opin Rheumatol, 2019, 31(6): 643-649.
|
| 30 |
András C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study [J]. J Rheumatol, 2008, 35(3): 438-444.
|
| 31 |
Moghadam-Kia S, Oddis CV, Ascherman DP, et al. Risk factors and cancer screening in myositis [J]. Rheum Dis Clin North Am, 2020, 46(3): 565-576.
|
| 32 |
Babu AK, Mizaj Z, Thomas J, et al. Clinical significance of myositis-specific and myositis-associated antibody profiles in dermatomyositis [J]. Indian Dermatol Online J, 2022, 14(1): 55-60.
|
| 33 |
Wu J, Qiu L, Wang Y, et al. Dermatomyositis on 68Ga-FAPI PET/CT in a patient with nasopharyngeal carcinoma [J]. Clin Nucl Med, 2022, 47(2): 149-150.
|
| 34 |
Oldroyd AGS, Allard AB, Callen JP, et al. A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies [J]. Rheumatology (Oxford), 2021, 60(6): 2615-2628.
|
| 35 |
王亚飞, 吴振彪. 自身抗体在皮肌炎患者管理中的应用 [J/OL]. 中华临床医师杂志(电子版), 2022, 16(8): 796-800.
|
| 36 |
Woo JH, Kim YJ, Kim JJ, et al. Mortality factors in idiopathic inflammatory myopathy: focusing on malignancy and interstitial lung disease [J]. Mod Rheumatol, 2013, 23(3): 503-508.
|
| 37 |
Khojah A, Liu V, Morgan G, et al. Changes in total body fat and body mass index among children with juvenile dermatomyositis treated with high-dose glucocorticoids [J]. Pediatr Rheumatol Online J, 2021, 19(1): 118.
|
| 38 |
Wiala A, Vujic I, Richter L, et al. Dermatomyositis erfordert eine kombinierte Langzeittherapie mit Immunsuppressiva und intravenösen Immunglobulinen [J]. J Dtsch Dermatol Ges, 2021, 19(3): 456-459. German.
|
| 39 |
Selva-O'Callaghan A, Trallero-Araguás E, Ros J, et al. Management of cancer-associated myositis [J]. Curr Treatm Opt Rheumatol, 2022, 8(4): 91-104.
|
| 40 |
Yang H, Ding Z, An Z, et al. Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study [J]. Expert Opin Drug Saf, 2024, 24: 1-6.
|
| 41 |
Corrado B, Ciardi G, Lucignano L. Supervised physical therapy and polymyositis/dermatomyositis-a systematic review of the literature [J]. Neurol Int, 2020, 12(3): 77-88.
|
| 42 |
Fukada A, Fujisawa T, Hozumi H, et al. Prognostic role of interferon-λ3 in anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated interstitial lung disease [J]. Arthritis Rheumatol, 2024, 76(5): 796-805.
|